MX2021009774A - Sal de un compuesto pentaciclico y su cristal. - Google Patents
Sal de un compuesto pentaciclico y su cristal.Info
- Publication number
- MX2021009774A MX2021009774A MX2021009774A MX2021009774A MX2021009774A MX 2021009774 A MX2021009774 A MX 2021009774A MX 2021009774 A MX2021009774 A MX 2021009774A MX 2021009774 A MX2021009774 A MX 2021009774A MX 2021009774 A MX2021009774 A MX 2021009774A
- Authority
- MX
- Mexico
- Prior art keywords
- crystals
- salt
- pentacyclic compound
- compound
- pentacyclic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019039349 | 2019-03-05 | ||
| PCT/JP2020/008889 WO2020179781A1 (ja) | 2019-03-05 | 2020-03-03 | 五環式化合物の塩およびそれらの結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009774A true MX2021009774A (es) | 2021-09-08 |
Family
ID=72337486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009774A MX2021009774A (es) | 2019-03-05 | 2020-03-03 | Sal de un compuesto pentaciclico y su cristal. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11420980B2 (https=) |
| EP (1) | EP3936189A4 (https=) |
| JP (1) | JP7508441B2 (https=) |
| KR (1) | KR102921161B1 (https=) |
| CN (1) | CN113646046B (https=) |
| AU (1) | AU2020233452B2 (https=) |
| BR (1) | BR112021015979A2 (https=) |
| CA (1) | CA3129764A1 (https=) |
| MX (1) | MX2021009774A (https=) |
| TW (2) | TWI870286B (https=) |
| WO (1) | WO2020179781A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020179780A1 (ja) | 2019-03-05 | 2020-09-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 五環式複素環化合物 |
| PT119624A (pt) * | 2024-07-29 | 2026-01-29 | Silva Escada Guilherme | Máquina modular para a dobragem de tubos de pvc |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4187306A (en) * | 1977-07-26 | 1980-02-05 | Bayer Aktiengesellschaft | Benzodiazepine-diones, a process for their production and their use as medicaments |
| DD258234A1 (de) | 1987-03-05 | 1988-07-13 | Univ Leipzig | Verfahren zur herstellung von pyrido/3',2':4,5/thieno/2,3-e/imidazo-/1,2-c/pyrimidinen sowie strukturanaloger -pyrimido/1,2-c/pyrimidine bzw. -1,3-diazepino/1,2-c/pyrimidine |
| RU2117670C1 (ru) | 1988-10-31 | 1998-08-20 | Эйсай Ко., Лтд. | Производные триазоло[1,4]диазепина и способы их получения |
| TW197442B (https=) * | 1990-02-08 | 1993-01-01 | Pfizer | |
| US5621100A (en) * | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | K-252a derivatives for treatment of neurological disorders |
| US5756494A (en) * | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
| KR100203456B1 (ko) * | 1995-06-20 | 1999-06-15 | 한승수 | 디하이드로에보디아민-에이치씨1를 유효성분으로 함유하는 알츠하이머병에 의한 치매 치료제 |
| CL2004000348A1 (es) | 1997-04-15 | 2005-01-14 | Cephalon Inc & Kyowa Hakko Kog | Compuesto derivado de estaurosporina bis-n-sustituida, util para potenciar la funcion de neuronas colinergicas, estriadas, del prosencefalo basal y sensoriales. |
| CL2004000352A1 (es) | 1998-05-26 | 2005-05-27 | Cephalon Inc & Kyowa Hakko Kog | Uso de compuestos derivados de estaurosporina para potenciar la funcion de neuronas colinergicas, estriadas, de prosencefalo basal y sensoriales. |
| FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| US8252520B2 (en) | 2002-10-11 | 2012-08-28 | Taivex Therapeutics Corporation | Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases |
| AU2005299031B2 (en) | 2004-10-20 | 2011-11-10 | F. Hoffmann-La Roche Ag | Halogen substituted benzodiazepine derivatives |
| US9314318B2 (en) * | 2008-08-26 | 2016-04-19 | Zest Ip Holdings, Llc | Dental anchor apparatus and method |
| JP6557441B1 (ja) * | 2017-09-07 | 2019-08-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 五環式化合物 |
| WO2020179780A1 (ja) | 2019-03-05 | 2020-09-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 五環式複素環化合物 |
-
2020
- 2020-03-03 WO PCT/JP2020/008889 patent/WO2020179781A1/ja not_active Ceased
- 2020-03-03 EP EP20766851.8A patent/EP3936189A4/en active Pending
- 2020-03-03 TW TW113114065A patent/TWI870286B/zh active
- 2020-03-03 KR KR1020217025603A patent/KR102921161B1/ko active Active
- 2020-03-03 TW TW109106928A patent/TWI849070B/zh active
- 2020-03-03 BR BR112021015979-7A patent/BR112021015979A2/pt unknown
- 2020-03-03 AU AU2020233452A patent/AU2020233452B2/en active Active
- 2020-03-03 MX MX2021009774A patent/MX2021009774A/es unknown
- 2020-03-03 JP JP2021504108A patent/JP7508441B2/ja active Active
- 2020-03-03 CA CA3129764A patent/CA3129764A1/en active Pending
- 2020-03-03 CN CN202080014060.2A patent/CN113646046B/zh active Active
- 2020-09-15 US US17/021,544 patent/US11420980B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3936189A1 (en) | 2022-01-12 |
| JP7508441B2 (ja) | 2024-07-01 |
| BR112021015979A2 (pt) | 2021-10-05 |
| KR20210135223A (ko) | 2021-11-12 |
| US11420980B2 (en) | 2022-08-23 |
| CN113646046A (zh) | 2021-11-12 |
| KR102921161B1 (ko) | 2026-02-02 |
| TWI849070B (zh) | 2024-07-21 |
| JPWO2020179781A1 (https=) | 2020-09-10 |
| CN113646046B (zh) | 2024-05-17 |
| AU2020233452A1 (en) | 2021-09-02 |
| EP3936189A4 (en) | 2022-12-14 |
| TW202430531A (zh) | 2024-08-01 |
| WO2020179781A1 (ja) | 2020-09-10 |
| AU2020233452B2 (en) | 2025-04-10 |
| TW202100531A (zh) | 2021-01-01 |
| US20210024541A1 (en) | 2021-01-28 |
| TWI870286B (zh) | 2025-01-11 |
| CA3129764A1 (en) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220155A1 (ar) | مشتقات البيرازول مفيدة كعوامل مضادة للسرطان | |
| SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| EP4071149A3 (en) | Heterocyclic compounds and uses thereof | |
| ZA202201503B (en) | Urea compound for antagonizing lpa1 receptor | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| ZA202208051B (en) | Protein degradation agent compound preparation method and application | |
| MX2015008975A (es) | Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| MX2017012295A (es) | Derivados formilados n-heterociclicos como inhibidores de fgfr4. | |
| ZA202002762B (en) | Benzimidazole derivatives and their uses | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| MX2020008110A (es) | Sal de compuesto de pirazolo[1,5-a]pirimidina y cristales de la misma. | |
| PH12021550439A1 (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| MX2016014946A (es) | Derivados de carboxamida. | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| MX2021009774A (es) | Sal de un compuesto pentaciclico y su cristal. | |
| JOP20200127A1 (ar) | مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية | |
| MX2024008024A (es) | Cristal de compuesto de piperidina sustituida, sales de compuesto de piperidina sustituida y cristales de estas. | |
| PH12022550529A1 (en) | Magl inhibitor, preparation method and use thereof | |
| PH12020551217A1 (en) | Benzodiazepine derivative hydrochloride and crystal form, preparation method and application thereof | |
| MX2019012380A (es) | Cristales de compuesto piranodipiridinico. | |
| WO2020163265A8 (en) | Medicament for prophylaxis or treatment of pulmonary fibrosis | |
| PH12016502247A1 (en) | Carboxamide derivatives |